Abstract
Oncolytic virotherapy is rapidly advancing into clinical practice as an appealing strategy for cancer therapy. Studies in the recent decades indicate that immunostimulatory properties of oncolytic viruses (OVs) are crucial for their therapeutic efficacy. The specific lysis of tumor cells and release of tumor associated antigens in the context of an OV infection ensures activation of a tumor-specific immune response. The evidence for induction of a systemic, specific antitumor immune response after OV therapy in preclinical and clinical studies allows to consider oncolytic virotherapy as a type of therapeutic cancer vaccination strategy.
This chapter describes methods to evaluate the therapeutic tumor vaccination effect of an oncolytic virus in murine tumor models. Protocols for a tumor rechallenge experiment in vivo and tumor cell specific splenocyte restimulation in vitro are included, as well as protocols for analysis of memory T cell subpopulations in tumor draining lymph nodes using flow cytometry.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Galluzzi L, Vacchelli E, Bravo-San Pedro J-M, Buqué A, Senovilla L, Baracco EE et al (2014) Classification of current anticancer immunotherapies. Oncotarget 5(24):12472–12508
Guo C, Manjili M, Subjeck J, Sarkar D, Fisher P, Wang X (2013) Therapeutic cancer vaccines: past, present and future. Adv Cancer Res 119:421–475
Russell SJ, Barber GN (2018) Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 33(4):599–605
Bell JC, McFadden G (2014) Viruses for tumor therapy John. Cell Host Microbe 15(3):260–265
Escors D (2014) Tumour immunogenicity, antigen presentation, and immunological barriers in cancer immunotherapy. N J Sci 2014:734515
Sánchez-Paulete DAR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I (2017) Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol 28(Suppl_12):44–55
Prestwich FRJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F (2008) Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 8(10):1581–1588
Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788
Galanis E, Atherton PJ, Maurer MJM, Knutson KL, Dowdy SC, Cliby WA et al (2014) Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 75(1):22–30
Lichty BD, Breitbach CJ, Stojdl DF, Bell JC (2014) Going viral with cancer immunotherapy. Nat Rev Cancer 14(8):559–567
Sobol PT, Boudreau JE, Stephenson K, Wan Y, Lichty BD, Mossman KL (2009) Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther 19(2):335–344
Li X, Wang P, Li H, Du X, Liu M, Huang Q et al (2017) The efficacy of oncolytic adenovirus is mediated by T-cell responses against virus and tumor in Syrian hamster model. Clin Cancer Res 23(1):239–249
Aitken A, Roy D, Bourgeois-Daigneault M-C (2017) Taking a stab at cancer; oncolytic virus-mediated anti-cancer vaccination strategies. Biomedicine 5(1):3
Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK et al (2014) CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22(11)
Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF et al (2013) Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 24(7):644–654
Speck T, Heidbuechel J, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE (2018) Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin Cancer Res 24(9):2128–2138
Veinalde R, Grossardt C, Hartmann L, Bourgeois-Daigneault M-C, Bell JC, Jäger D et al (2017) Oncolytic measles virus encoding interleukin-12 mediates potent anti-tumor effects through T cell activation. OncoImmunology 6(4):e1285992
Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J (1991) Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51(14):3657–3662
Cossarizza A, Chang H, Radbruch A, Annunziato F, Bacher P, Barnaba V et al (2017) Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol 47(10):1584–1797
Puré E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7(5):213–221
Sallusto MF, Lenig D, Förster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708–712
Veinalde R (2017) Unraveling determinants of efficacy in measles immunovirotherapy. Ruprecht-Karls-Universität Heidelberg, Heidelberg
Acknowledgments
The author acknowledges Dr. C. E. Engeland for support and consultation for development of the described protocols. This work was supported by the European Regional Development Fund project no. 1.1.1.2/VIAA/2/18/292 (1.1.1.2/16/I/001).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Veinalde, R. (2020). Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models. In: Engeland, C. (eds) Oncolytic Viruses. Methods in Molecular Biology, vol 2058. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9794-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9794-7_13
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9793-0
Online ISBN: 978-1-4939-9794-7
eBook Packages: Springer Protocols